- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770575
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease
Double Blinded Study of the Effects of Pioglitazone in Combination With Atorvastatin in Comparison to Atorvastatin Treatment Alone on Intima-Media Thickness in Patients at Risk for Vascular Complications
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Carotid intima-media thickness is a well described surrogate marker for cardiovascular risk. A thickened carotid intima media layer correlates not only with the presence of cardiovascular risk factors but also the risk of future macrovascular events such as myocardial infarction and stroke. The interventional approach of cardiovascular risk factors with angiotensin converting enzyme system blockers, calcium antagonists or beta blockers can result in reduction of progression or even net regression of carotid intima-media thickness. The most potent agents, however, are statins which have consistently shown effects on carotid intima-media thickness in patients with hypercholesterolemia and/or atherosclerotic disease.
Peroxisome proliferator activator receptor-gamma activation by thiazolidinediones is a promising new approach which reduces insulin resistance and improves lipid profile. In addition to their metabolic activities, peroxisome proliferator activator receptor-gamma activators were shown to exert anti-inflammatory effects, to improve endothelial function and to inhibit atherogenesis in diabetic and in non-diabetic atherosclerosis-prone animal models. Treatment with peroxisome proliferator activator receptor-gamma agonists have shown to reduce arterial pressure and carotid intima-media thickness in diabetic and non-diabetic patients at risk for cardiovascular disease.
The aim of this study is to evaluate the effect of Pioglitazone in addition to Atorvastatin compared to Atorvastatin alone on vascular risk markers and intima-media thickness in patients with elevated risk for cardiovascular disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Intima-media thickness of Common Carotid Artery greater than or equal to 0.8 mm (at least on one side).
Increased cardiovascular risk defined as one or more of the following:
- medical history of infarction
- coronary angiography with proven cardiovascular disease
- instable Angina pectoris
- duplex-sonography of cervical or leg vessels with proven atherosclerotic vascular alterations
- electrocardiogram with ischemia
- stroke
- transient ischemic attack
- peripheral arterial occlusion
- vessel surgery
- hypertension (RR greater than 140/90)
- antihypertensives
- high density lipoprotein less than 40 mg/dl.
- Body mass index greater than or equal to 25 kg/m2.
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
Exclusion Criteria:
- History of overt type-2-diabetes according to the World Health Organization criteria.
- History of type-1-diabetes.
- History of more than one unexplained hypoglycemic episode within the last 6 months.
- Statin therapy within the last 4 weeks.
- Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.
- History of severe or multiple allergies.
- Treatment with any other investigational drug within 3 months before trial entry.
- Progressive fatal disease.
- Myopathy.
- Drug or alcohol abuse within the last 5 years.
- Smoker defined as patient with evidence or history of tobacco or nicotine use within the last 6 months before the screening visit.
- A history of heart failure (New York Heart Association stage II - IV) or significant respiratory, gastrointestinal, hepatic (glutamate-pyruvate-transaminase time greater than 2.5 times the normal reference range), renal (creatinine greater than 2.0 mg/dl) or hematological disease.
- Blood donation within the last 30 days.
Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- ciclosporin
- erythromycin
- clarithromycin
- itraconazole
- ketoconazole
- nefazodone
- niacin
- gemfibrozil and other fibrates
- HIV-Protease-Inhibitors
- Pre-treatment with thiazolidinediones within 3 months before trial entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD
|
Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to: Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
Other Names:
|
Active Comparator: Atorvastatin 20mg to 40 mg QD
|
Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the intima-media thickness of the common carotid artery.
Time Frame: Week 24.
|
Week 24.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the intima-media thickness of the internal carotid artery.
Time Frame: Week 24.
|
Week 24.
|
Change in the intima-media thickness of the carotid bulbus.
Time Frame: Week 24.
|
Week 24.
|
Change from Baseline in Efficacy Laboratory findings (Interleukin-6, high sensitive C reactive peptide and monocyte chemotactic protein-1)
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Efficacy Laboratory findings (matrix metalloproteinase-9, soluble CD40 Ligand, P-Selectin, soluble intracellular adhesion molecule 1 and soluble vascular cell adhesion molecule 1).
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Efficacy Laboratory findings (adiponectin, tissue plasminogen activator, Plasma glucose, Insulin and Intact proinsulin).
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Efficacy Laboratory findings (blood lipids (total cholesterol, high density lipoprotein, triglycerides) and low density lipoprotein-subfractions).
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Glycosylated Hemoglobin.
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Beta cell function (Homeostatic Model Assessment - beta cell response Score).
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Insulin sensitivity using the Homeostatic Model Assessment - Sensitivity Score).
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Microcirculation assessment.
Time Frame: Week: 24.
|
Week: 24.
|
Change from Baseline in Pulse wave velocity.
Time Frame: Weeks: 12 and 24.
|
Weeks: 12 and 24.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Head of Clinical Research/Licensing/New Products, Takeda Pharma Gmbh, Aachen (Germany)
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATS K015
- 2004-004463-30 (EudraCT Number)
- D-PIO-106 (Other Identifier: Takeda ID)
- U1111-1115-9124 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Pioglitazone and atorvastatin
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedInsulin Resistance | Intermittent Claudication | Arterial Occlusive DiseaseUnited States
-
The Catholic University of KoreaJeil Pharmaceutical Co., Ltd.TerminatedCoronary Artery Disease | AtherosclerosisKorea, Republic of
-
Brooke Army Medical CenterCompleted
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States